SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has expanded its international footprint with the launch of Sri Lanka’s first robotic cardiac surgery program at Kings Hospital Colombo, powered by its SSi Mantra 3.0 surgical robotic system. The program commenced with a robotic-assisted left internal mammary artery takedown performed by company founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. According to the company, the hospital completed more than 25 robotic procedures within the first three weeks, demonstrating rapid adoption of the technology in a new market.
The launch adds to SS Innovations’ international expansion. At the end of the second quarter of 2026, the company reported 224 cumulative SSi Mantra installations across 12 countries. Quarterly revenue increased 39% year over year to $13.9 million, while robotic procedures rose 143% to 2,528. These figures highlight increased utilization of its installed systems and potential opportunities for recurring revenue from surgical instruments and consumables. The company is also pursuing broader market access, with U.S. FDA clearance targeted for the first quarter of 2027 and European CE marking targeted for the end of 2026. For a detailed view of the announcement, visit https://nnw.fm/DJ6dI.
SS Innovations develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. More information is available at SSInnovations.com or through the company’s newsroom at https://nnw.fm/SSII.
The news matters because it signals growing global demand for robotic-assisted surgery, particularly in cardiac care, where precision and minimally invasive techniques can improve patient outcomes. For SS Innovations, the Sri Lanka program serves as a showcase for its technology in a new region and supports its broader regulatory and commercial ambitions. The company’s revenue and procedure growth suggest that its installed base is generating recurring instrument and consumable sales, a key metric for long-term financial health. As SS Innovations pursues FDA and CE mark clearances, successful international deployments like the one at Kings Hospital Colombo could bolster its credibility with regulators, investors, and healthcare providers.
For investors and industry observers, the announcement provides insight into SS Innovations’ operational momentum. The full article is available through https://nnw.fm/DJ6dI, and the company’s latest updates are available in its newsroom at https://nnw.fm/SSII. The announcement was distributed via NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
